Concepedia

Publication | Closed Access

Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis.

DOI

171

Citations

12

References

1992

Year

Dirk Th. Sleijfer, René A. J. Janssen, Jan Buter, Elisabeth G.E. de Vries, P.H.B. Willemse, Nanno H. Mulder
Journal of Clinical Oncology

Abstract

Subcutaneous IL-2 is clinically active, has an acceptable toxicity, and can be given to patients with concomitant disease.

References

YearCitations

Page 1